Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (301-310 of 436) with videos related to

Pageof 44
Sort By:
American Heart Journal|May 21, 2019
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAxel Åkerblom, Daniel M Wojdyla, Lars Wallentin, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 22, 2008
G-protein-coupled receptors as signaling targets for antiplatelet therapySusan S Smyth, Donna S Woulfe, Jeffrey I Weitz, et al.
Circulation. Cardiovascular Quality and Outcomes|September 20, 2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trialSteen Husted, Stefan James, Richard C Becker, et al.
International Journal of Cardiology|December 5, 2013
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
International Journal of Cardiology|July 10, 2014
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
Clinical Cardiology|June 10, 2017
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trialCharles V Pollack, Farideh Davoudi, Deborah B Diercks, et al.
The Annals of Pharmacotherapy|June 19, 2008
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation ForumDavid A Garcia, Daniel M Witt, Elaine Hylek, et al.
The American Journal of Cardiology|September 6, 2011
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy)Robert F Storey, Richard C Becker, Robert A Harrington, et al.
Atherosclerosis|December 14, 2019
ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trialThor Ueland, Axel Åkerblom, Tatevik Ghukasyan, et al.
Circulation. Cardiovascular Interventions|April 19, 2012
Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responsesJesse W Rowley, Aloke V Finn, Patricia A French, et al.
Pageof 44

Showing results (301-310 of 436) with videos related to

Sort By:
Pageof 44
American Heart Journal|May 21, 2019
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAxel Åkerblom, Daniel M Wojdyla, Lars Wallentin, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 22, 2008
G-protein-coupled receptors as signaling targets for antiplatelet therapySusan S Smyth, Donna S Woulfe, Jeffrey I Weitz, et al.
Circulation. Cardiovascular Quality and Outcomes|September 20, 2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trialSteen Husted, Stefan James, Richard C Becker, et al.
International Journal of Cardiology|December 5, 2013
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
International Journal of Cardiology|July 10, 2014
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
Clinical Cardiology|June 10, 2017
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trialCharles V Pollack, Farideh Davoudi, Deborah B Diercks, et al.
The Annals of Pharmacotherapy|June 19, 2008
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation ForumDavid A Garcia, Daniel M Witt, Elaine Hylek, et al.
The American Journal of Cardiology|September 6, 2011
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy)Robert F Storey, Richard C Becker, Robert A Harrington, et al.
Atherosclerosis|December 14, 2019
ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trialThor Ueland, Axel Åkerblom, Tatevik Ghukasyan, et al.
Circulation. Cardiovascular Interventions|April 19, 2012
Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responsesJesse W Rowley, Aloke V Finn, Patricia A French, et al.
Pageof 44